/

Società

Si

Non verificato

Sironax USA, Inc.

Di cosa scriviamo

Annunci EconomiciBiotecnologiaFinanzaMedicina Salute Benessere

10 comunicati stampa

Guarda tutti i comunicati

29/10/2026

Biotecnologia

Sironax Announces Three Abstracts on SARM1 Inhibitor SIR2501 Selected for Presentation at Neuroscience 2026

Fonte

Sironax USA, Inc.

Emittente

1.00

0

13/10/2026

Biotecnologia

Medicina Salute Benessere

Sironax Advances Enrollment in Phase 2 FORGE-LM Obesity Trial of NAMPT Activator SIR4156

Fonte

Sironax USA, Inc.

Emittente

1.00

0

05/10/2026

Biotecnologia

Annunci Economici

Sironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026

Fonte

Sironax USA, Inc.

Emittente

1.00

0

16/09/2026

Biotecnologia

Finanza

Sironax Announces Option Exercise and Asset Purchase

Fonte

Sironax USA, Inc.

Emittente

1.00

0

11/05/2026

Biotecnologia

Sironax’s SARM1 Inhibitor SIR2501 Granted FDA Fast Track Designation in Chemotherapy-induced Peripheral Neuropathy (CIPN)

Fonte

Sironax USA, Inc.

Emittente

1.00

0

22/04/2026

Biotecnologia

Sironax Announces Abstract on SARM1 Inhibitor SIR2501 Selected for Presentation at 2026 ASCO Annual Meeting

Fonte

Sironax USA, Inc.

Emittente

1.00

0

26/03/2026

Biotecnologia

Sironax Appoints Clive Wang to Board of Directors

Fonte

Sironax USA, Inc.

Emittente

1.00

0

20/03/2026

Biotecnologia

Sironax Announces Upcoming Poster Presentation on NAMPT Activation

Fonte

Sironax USA, Inc.

Emittente

1.00

0

06/11/2025

Biotecnologia

Medicina Salute Benessere

Sironax Announces Three Abstracts Selected for Presentation at Neuroscience 2025

Fonte

Sironax USA, Inc.

Emittente

1.00

0

22/10/2025

Biotecnologia

Medicina Salute Benessere

Sironax Announces Key Leadership Appointments to Advance Global Drug Discovery and Development

Fonte

Sironax USA, Inc.

Emittente

1.00

0

Seguaci

0

Compatibilità

0